伪基MAPK6P4编码的功能性促进了质母细胞瘤血管原体模仿的发展
Mengyang Zhang1,2,3, Yubo Zhao4,5,6, Xiaobai Liu4,5,6
1Department of Neurobiology, School of Life Sciences, China Medical University, Shenyang, 110122, PR China.
Communications biology
|October 18, 2023
概括
伪基MAPK6P4缺陷通过抑制关键蛋白表达来抑制质母细胞瘤 (GBM) 的进展和血管仿真 (VM). 这项研究确定了一种影响GBM VM的新途径,为质瘤治疗提供了潜在的新治疗点.
科学领域:
- 神经瘤学神经瘤学
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 质瘤,特别是质母细胞瘤 (GBM),是一种高度恶性脑瘤,治疗结果不佳.
- 血管生成模仿 (VM) 是瘤血管生成的替代方案,阻碍了质瘤的抗血管生成疗法.
- 在瘤中,VEGFR2和VE-cadherin是VM的已知分子标记物.
研究的目的:
- 调查伪基MAPK6P4在GBM扩散,入侵和VM中的作用.
- 阐明MAPK6P4影响GBM VM形成的分子机制.
- 为了确定质瘤治疗的潜在治疗点.
主要方法:
- 在体外测试评估GBM细胞的增殖,迁移和入侵.
- 西方涂抹和免疫光学分析蛋白质表达 (VEGFR2,VE-cadherin,KLF15,LDHA).
- 在体内研究中,使用了GBM的正位体和皮下异种移植裸体小鼠模型.
主要成果:
- MAPK6P4 缺陷显著抑制了 VEGFR2 和 VE-cadherin 的表达,抑制了 GBM 细胞的增殖,迁移,入侵和 VM.
- MAPK6P4编码的P4-135aa通过化KLF15促进了GBM VM,从而提高了其稳定性和核进入.
- KLF15激活了LDHA,这促进了VEGFR2和VE-cadherin的乳酸化,增加了它们的蛋白质水平.
结论:
- 伪基MAPK6P4在通过KLF15-LDHA轴促进GBMVM形成方面发挥着至关重要的作用.
- 准MAPK6P4/P4-135aa/KLF15/LDHA通路为综合性质瘤治疗提供了一个潜在的战略.
- 这项研究揭示了克服质母细胞瘤治疗耐药性的新型分子标.
相关概念视频
MAPK Signaling Cascades
5.6K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.6K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K


